Abstract
Chemotherapy for malignant brain tumors has a limited efficacy largely due to restricted blood–brain barrier permeability for chemotherapeutic drugs. Intraarterial chemotherapy (IAC) has the advantage of increased uptake during the first passage of the drugs through tumor capillaries. Initial IAC trials had less than satisfactory results due to unacceptable toxicities. Between 1987 and 1996, 173 patients with primary and metastatic brain tumors were treated with intraarterial (intracarotid and/or intravertebral) cisplatin and etoposide (VP-16). Out of these, 168 patients, who received a total of 438 cycles, were evaluated for the incidence of toxicities. Patients received either cisplatin at 40 mg/m2 and VP-16 at 20 mg/m2 or cisplatin at 60 mg/m2 and VP-16 at 40 mg/m2. Nausea and vomiting were the most common toxicities (42 patients, 14% of cycles). Arterial puncture was associated with a 1.6% incidence of groin hematomas (6 patients), and a 0.7% incidence of failure to canulate the carotid or vertebral arteries (3 patients). Neurologic toxicities included headache (1.4% of cycles, 5 patients), focal seizures (1.4% of cycles, 5 patients), transient confusion and urinary retention/incontinence (1.9% of cycles, 8 patients), and blurred vision (0.9% of cycles, 4 patients). We have not seen visual loss, strokes, major vessel dissection or thrombosis, or myelosuppression. Toxicity incidence was higher in patients with metastatic brain tumors than in those with primary brain tumors (34% versus 17%, p<0.001). It was also higher in patients who had brain radiation therapy (RT) prior to IAC than in those who had RT concomitant with IAC (31% versus 19%, p=0.05). No significant difference in toxicity incidence was noticed between patients who received RT concomitant with IAC and those who received RT after IAC (19% and 23% respectively, p=0.08). Intracarotid chemotherapy given prior to RT resulted in 23 months of median survival for patients with glioblastoma multiforme. Intraarterial chemotherapy with cisplatin and VP-16 is a relatively safe treatment modality, especially in patients with primary brain tumors who have not received brain radiotherapy.
Similar content being viewed by others
References
Green SB, Byar DP, Walker MD: Comparisons of carmustine, procarbazine, and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121–132, 1983
Shapiro WR, Ausman JI: The chemotherapy of brain tumors: A clinical and experimental review. In: Plum F, McDowell FH (eds) Recent Advances in Neurology. FADavis Company, Philadelphia, 1969, pp 149–235
Fenstermacher JD, Cowles AL: Thearectic limitations of intracarotid infusions in brain tumor chemotherapy. Cancer Treat Rep 61: 518–526, 1977
Greenberg HS, Ensminger WD, Chandler WF: Intra-arterial BCNU Chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg 61: 423–429, 1984
Shapiro W, Green S, Burger P, Selker R: A randomized comparison of intra-arterial versus intravenous BCNU, with and without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76: 772–781, 1992
Stewart DJ, Leavens M, Maor M et al.: Humancentral nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982
Savarej N, Lu K, Raulston GL, Feun LG, Loo TL: Comparison of CNS penetration, tissue distribution, and pharmacology of 40-demethylepipodophyllotoxin 9-(4,6–0-ethylidene-beta-D-glucopyranoside) (VP-16, NSC-141540) intracarotid (IC) versus intravenous administration (IV) in dogs (Abstract). Proc Am Assoc Cancer Res 23: 201, 1982
Feun LG, Wallace S, Stewart DJ, Chuang V, Yung W: Intracarotid infusion of cis-diamminodichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984
Lehane DE, Ehni G, Bryan N, Horowitz B, Harper R, Aldama A: Adjuvant therapy for patients with high grade malignant gliomas using intra-arterial cisplatinum, CCNU and radiaton therapy. In: Jones SE, Salmon SE (eds) Adjuvant Therapy of Cancer IV. Grune & Stratton, New York, 1984, pp 81–88
Madajewicz S, West CR, Tyson C: Intra-carotid/vertebral chemotherapy of high grade astrocytomas and metastatic brain tumors – Evaluation of regional approach and different agents. J Cancer Res Clin Oncol 116 (Suppl. part I): 408, 1990
Madajewicz S, Chowhan N, Iliya A, Roque C, Beaton R: Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 67: 2844–2849, 1991
Madajewicz S, Meek A, Davis R: Novel first line therapy for malignant astrocytomas (Abstract). Proceedings ofASCO13: 178, 1994
Hiesiger E, Green S, Shapiro W, Burger P et al.: Results of a randomised trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neurooncol 25: 143–154, 1995
Fernandez-Hidalco OA, Vanaclocha V, Vieitez JM, Brugarolas A: High dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplantation 18: 143–149, 1996.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arafat, T., Patricia, H., Stefan, M. et al. Toxicities Related to Intraarterial Infusion of Cisplatin and Etoposide in Patients with Brain Tumors. J Neurooncol 42, 73–77 (1999). https://doi.org/10.1023/A:1006116523041
Issue Date:
DOI: https://doi.org/10.1023/A:1006116523041